AAAAAA

   
Results: 1-13 |
Results: 13
Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure
Authors: Mirochnick, M Siminski, S Fenton, T Lugo, M Sullivan, JL
Citation: M. Mirochnick et al., Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure, PEDIAT INF, 20(8), 2001, pp. 803-805
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)
Authors: Eshleman, SH Mracna, M Guay, LA Deseyve, M Cunningham, S Mirochnick, M Musoke, P Fleming, T Fowler, MG Mofenson, LM Mmiro, F Jackson, JB
Citation: Sh. Eshleman et al., Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012), AIDS, 15(15), 2001, pp. 1951-1957
Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection
Authors: Mirochnick, M Cooper, E Capparelli, E McIntosh, K Lindsey, J Xu, J Jacobus, D Mofenson, L Bonagura, VR Nachman, S Yogev, R Sullivan, JL Spector, SA
Citation: M. Mirochnick et al., Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection, CLIN PHARM, 70(1), 2001, pp. 24-32
Bioequivalence of a propylene glycol-based liquid dapsone preparation and dapsone tablets
Authors: Mirochnick, M Clarke, DF McNamara, ER Cabral, H
Citation: M. Mirochnick et al., Bioequivalence of a propylene glycol-based liquid dapsone preparation and dapsone tablets, AM J HEAL S, 57(19), 2000, pp. 1775-1777
Nevirapine - Pharmacokinetic considerations in children and pregnant women
Authors: Mirochnick, M Clarke, DF Dorenbaum, A
Citation: M. Mirochnick et al., Nevirapine - Pharmacokinetic considerations in children and pregnant women, CLIN PHARMA, 39(4), 2000, pp. 281-293
Identification of the K103N resistance mutation in Ugandan women receivingnevirapine to prevent HIV-1 vertical transmission
Authors: Jackson, JB Becker-Pergola, G Guay, LA Musoke, P Mracna, M Fowler, MG Mofenson, LM Mirochnick, M Mmiro, F Eshleman, SH
Citation: Jb. Jackson et al., Identification of the K103N resistance mutation in Ugandan women receivingnevirapine to prevent HIV-1 vertical transmission, AIDS, 14(11), 2000, pp. F111-F115
Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus
Authors: McIntosh, K Cooper, E Xu, J Mirochnick, M Lindsey, J Jacobus, D Mofenson, L Yogev, R Spector, SA Sullivan, JL Sacks, H Kovacs, A Nachman, S Sleasman, J Bonagura, V McNamara, J
Citation: K. Mcintosh et al., Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus, PEDIAT INF, 18(5), 1999, pp. 432-439
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)
Authors: Musoke, P Guay, LA Bagenda, D Mirochnick, M Nakabiito, C Fleming, T Elliott, T Horton, S Dransfield, K Pav, JW Murarka, A Allen, M Fowler, MG Mofenson, L Hom, D Mmiro, F Jackson, JB
Citation: P. Musoke et al., A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006), AIDS, 13(4), 1999, pp. 479-486
Cocaine absorption after application of a viscous cocaine-containing TAC solution
Authors: Vinci, RJ Fish, S Mirochnick, M
Citation: Rj. Vinci et al., Cocaine absorption after application of a viscous cocaine-containing TAC solution, ANN EMERG M, 34(4), 1999, pp. 498-502
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVMET 012 randomised trial
Authors: Guay, LA Musoke, P Fleming, T Bagenda, D Allen, M Nakabiito, C Sherman, J Bakaki, P Ducar, C Deseyve, M Emel, L Mirochnick, M Fowler, MG Mofenson, L Miotti, P Dransfield, K Bray, D Mmiro, F Jackson, JB
Citation: La. Guay et al., Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVMET 012 randomised trial, LANCET, 354(9181), 1999, pp. 795-802
Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children
Authors: Mirochnick, M Cooper, E McIntosh, K Xu, J Lindsey, J Jacobus, D Mofenson, L Sullivan, JL Dankner, W Frenkel, LM Nachman, S Wara, DW Johnson, D Bonagura, VR Rathore, MH Cunningham, CK McNamara, J
Citation: M. Mirochnick et al., Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children, ANTIM AG CH, 43(11), 1999, pp. 2586-2591
Level of in utero cocaine exposure and neonatal ultrasound findings
Authors: Frank, DA McCarten, KM Robson, CD Mirochnick, M Cabral, H Park, H Zuckerman, B
Citation: Da. Frank et al., Level of in utero cocaine exposure and neonatal ultrasound findings, PEDIATRICS, 104(5), 1999, pp. 1101-1105
Pharmacokinetics of zidovudine in infants: A population analysis across studies
Authors: Mirochnick, M Capparelli, E Connor, J
Citation: M. Mirochnick et al., Pharmacokinetics of zidovudine in infants: A population analysis across studies, CLIN PHARM, 66(1), 1999, pp. 16-24
Risultati: 1-13 |